3 Fermentation Based Pharma Ingredients Maker, Defence Electronics Company and Personal Care Brands Company Stocks With a Strong Future Roadmap: Concord Biotech, Bharat Electronics and Honasa Consumer

Biotech ingredient, defence and beauty stocks give investors a way to track businesses that sit close to everyday demand in India. Concord Biotech, Bharat Electronics and Honasa Consumer cover a fermentation based pharma ingredients maker, a defence electronics company and a personal care brands company.

This list covers three biotech ingredient, defence and beauty stocks with complete current figures: Concord Biotech, Bharat Electronics and Honasa Consumer. Every figure comes from the latest reported financials and the 9 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Biotech Ingredient, Defence and Beauty Stocks?

Biotech ingredient, defence and beauty stocks are listed companies that make fermentation based active pharmaceutical ingredients, build radars, communication and electronic systems for defence, and sell skincare, haircare and personal care brands. Their earnings depend on pharma sourcing, defence orders and household spending.

Biotech Ingredient, Defence and Beauty Stocks at a Glance

On valuation, Bharat Electronics trades at a P/E below the industry P/E, while Concord Biotech and Honasa Consumer trade above it, which reflects the growth the market already expects. Readers comparing biotech ingredient, defence and beauty stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in biotech ingredient, defence and beauty stocks can use the coming numbers to test whether growth is holding.

Why Do Biotech Ingredient, Defence and Beauty Stocks Have a Strong Roadmap in India?

Biotech ingredient, defence and beauty stocks have a strong roadmap in India because rising global demand for specialty pharma ingredients, strong defence indigenisation and fast growth in digital first beauty brands keep widening the market for these companies.

• Pharma ingredients. Drug makers need reliable fermentation inputs.
• Defence electronics. Armed forces need home built systems.
• Personal care. Shoppers try newer beauty brands.

Why Concord Biotech Features Among These Biotech Ingredient, Defence and Beauty Stocks

Among the biotech ingredient, defence and beauty stocks on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.

In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%.

Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.

Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What to watch: Monitor the pace of new product introductions and the contribution from formulations.

Why Bharat Electronics Features Among These Biotech Ingredient, Defence and Beauty Stocks

Among the fermentation, radar and personal care shares on this list, Bharat Electronics is a Navratna public sector company that designs and makes radars, communication systems, electronic warfare suites, naval systems, electro-optics and avionics for the Indian armed forces, with a growing civil and export business.

The company has a return on equity of 25.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 275,177 crore. The stock trades at a P/E of 44.8, below the industry P/E of 48.1.

Revenue rose from Rs 15,600 crore in FY22 to Rs 28,176 crore in FY26, a compound annual growth rate of 15.9%. Net profit grew from Rs 2,354 crore in FY22 to Rs 6,023 crore in FY26, which works out to a compound annual growth rate of 26.5%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 5,717 crore, while net profit rose 8.7% to Rs 1,044 crore.

Roadmap: The company works with a large order book from the defence ministry and continues to win new programmes in air defence, naval combat systems and communication. Indigenisation policies favour domestic suppliers, and the company is also widening into homeland security, railways and electronic manufacturing services.

What to watch: Watch the size of the order book, the pace of order execution and the order inflow reported with each quarterly result.

Why Honasa Consumer Features Among These Biotech Ingredient, Defence and Beauty Stocks

Among the three companies on this list, Honasa Consumer, based in Gurugram, owns beauty and personal care brands including Mamaearth, The Derma Co, Aqualogica and Dr. Sheth's.

Revenue rose from Rs 964 crore in FY22 to Rs 2,476 crore in FY26, a compound annual growth rate of 26.6%. Net profit grew from Rs 111 crore in FY24 to Rs 200 crore in FY26, which works out to a compound annual growth rate of 34.6%.

In the June 2026 quarter, revenue grew 25.7% year on year to Rs 778 crore, while net profit rose 118.8% to Rs 90.5 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 14,399 crore. The stock trades at a P/E of 57.7, above the industry P/E of 52.5.

Roadmap: The company is growing its brand portfolio, widening offline retail and building a presence in premium segments. A digital-first approach and a growing base of repeat customers support its roadmap.

What to watch: Track brand-level growth and spending on advertising.

Concord Biotech vs Bharat Electronics vs Honasa Consumer on Key Financials

The table below sets the three biotech ingredient, defence and beauty stocks side by side on revenue, profit and margin, using reported figures.

Bharat Electronics posts the highest return on equity in this group at 25.3%. Bharat Electronics has the largest FY26 revenue at Rs 28,176 crore, and Honasa Consumer shows the fastest revenue growth with a 26.6% compound annual rate. A useful habit with biotech ingredient, defence and beauty stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several fermentation drug input, radar maker and skincare stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Biotech Ingredient, Defence and Beauty Stocks

Every theme carries risks that deserve a check before any decision. For these biotech ingredient, defence and beauty stocks, the main points are: Long-term fermentation, radar and personal care shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Order timing. Defence and space orders can shift between periods.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter biotech ingredient, defence and beauty stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Biotech Ingredient, Defence and Beauty Stocks

Biotech ingredient, defence and beauty stocks work best when investors track growth, valuation and return on equity side by side. Concord Biotech, Bharat Electronics and Honasa Consumer each have a clear plan to grow. Based on the 9 November 2026 close, Concord Biotech trades at Rs 612.2, Bharat Electronics at Rs 397.7 and Honasa Consumer at Rs 470.05. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these biotech ingredient, defence and beauty stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track biotech ingredient, defence and beauty stocks, set price alerts and get research-backed stock ideas.

What are biotech ingredient, defence and beauty stocks?

Ans. Biotech ingredient, defence and beauty stocks are listed companies that make fermentation based active pharmaceutical ingredients, build radars, communication and electronic systems for defence, and sell skincare, haircare and personal care brands. Their earnings depend on pharma sourcing, defence orders and household spending. This list looks at three of them, Concord Biotech, Bharat Electronics and Honasa Consumer, using reported FY22 to FY26 financials and the 9 November 2026 closing prices.

Which biotech ingredient, defence and beauty stocks are covered in this list?

Ans. This list covers Concord Biotech, Bharat Electronics and Honasa Consumer. Based on the 9 November 2026 close, Concord Biotech traded at Rs 612.2, Bharat Electronics at Rs 397.7 and Honasa Consumer at Rs 470.05. Their return on equity ranges from 12.9% to 25.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 26.6%.

Why do biotech ingredient, defence and beauty stocks have a strong future roadmap in India?

Ans. Biotech ingredient, defence and beauty stocks have a strong roadmap in India because rising global demand for specialty pharma ingredients, strong defence indigenisation and fast growth in digital first beauty brands keep widening the market for these companies. The main drivers are as follows. Pharma ingredients. Drug makers need reliable fermentation inputs. Defence electronics. Armed forces need home built systems. Personal care. Shoppers try newer beauty brands. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Concord Biotech performed financially?

Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

How has Bharat Electronics performed financially?

Ans. Revenue rose from Rs 15,600 crore in FY22 to Rs 28,176 crore in FY26, a compound annual growth rate of 15.9%. Net profit grew from Rs 2,354 crore in FY22 to Rs 6,023 crore in FY26, which works out to a compound annual growth rate of 26.5%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 5,717 crore, while net profit rose 8.7% to Rs 1,044 crore. The company has a return on equity of 25.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 275,177 crore. The stock trades at a P/E of 44.8, below the industry P/E of 48.1. Looking ahead, the company works with a large order book from the defence ministry and continues to win new programmes in air defence, naval combat systems and communication. Indigenisation policies favour domestic suppliers, and the company is also widening into homeland security, railways and electronic manufacturing services.

How has Honasa Consumer performed financially?

Ans. Revenue rose from Rs 964 crore in FY22 to Rs 2,476 crore in FY26, a compound annual growth rate of 26.6%. Net profit grew from Rs 111 crore in FY24 to Rs 200 crore in FY26, which works out to a compound annual growth rate of 34.6%. In the June 2026 quarter, revenue grew 25.7% year on year to Rs 778 crore, while net profit rose 118.8% to Rs 90.5 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 14,399 crore. The stock trades at a P/E of 57.7, above the industry P/E of 52.5. Looking ahead, the company is growing its brand portfolio, widening offline retail and building a presence in premium segments. A digital-first approach and a growing base of repeat customers support its roadmap.

What risks should investors check before buying biotech ingredient, defence and beauty stocks?

Ans. Investors should check a few risks before buying biotech ingredient, defence and beauty stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Defence and space orders can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of biotech ingredient, defence and beauty stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 9 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.